within Pharmacolibrary.Drugs.ATC.A;

model A04AD14
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.97,
    Cl             = 0.00012033333333333334,
    adminDuration  = 600,
    adminMass      = 180 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.462,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0003333333333333333,
    Tlag           = 1800,            
    Vdp             = 0.353,
    k12             = 16.7,
    k21             = 16.7
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A04AD14</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Rolapitant is a selective neurokinin 1 (NK1) receptor antagonist used to prevent delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic chemotherapy. It is approved for use in this indication and is administered in combination with other antiemetic agents.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects after a single 180 mg oral dose.</p><h4>References</h4><ol><li><p>Wang, X, et al., &amp; Kansra, V (2019). Population Pharmacokinetics of Rolapitant in Patients With Chemotherapy-Induced Nausea and Vomiting. <i>Clinical pharmacology in drug development</i> 8(7) 850–860. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.733&quot;>10.1002/cpdd.733</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31418538/&quot;>https://pubmed.ncbi.nlm.nih.gov/31418538</a></p></li><li><p>Wang, J, et al., &amp; Kansra, V (2018). Pharmacokinetics of Rolapitant in Patients With Mild to Moderate Hepatic Impairment. <i>Journal of clinical pharmacology</i> 58(5) 686–693. DOI:<a href=&quot;https://doi.org/10.1002/jcph.1066&quot;>10.1002/jcph.1066</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29329482/&quot;>https://pubmed.ncbi.nlm.nih.gov/29329482</a></p></li><li><p>Wang, X, et al., &amp; Kansra, V (2017). Bioequivalence of Intravenous and Oral Rolapitant: Results From a Randomized, Open-Label Pivotal Study. <i>Journal of clinical pharmacology</i> 57(12) 1600–1606. DOI:<a href=&quot;https://doi.org/10.1002/jcph.966&quot;>10.1002/jcph.966</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28906561/&quot;>https://pubmed.ncbi.nlm.nih.gov/28906561</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A04AD14;
